DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactOrders & Deals

Alembic Pharmaceuticals Limited — Acquisition of 'to be incorporated companies'-XBRL

NSE 1 hr ago·20 Oct 2026, 7:14 am

Alembic Pharmaceuticals

Alembic Pharmaceuticals Limited has announced plans to acquire companies that are currently being incorporated. This strategic move involves the company purchasing the shares of these new entities once they are formed.

This acquisition is significant for investors as it signals Alembic's intent to expand its business portfolio. By integrating these new companies, the firm aims to strengthen its market position and diversify its operations.

Investors should monitor the progress of these incorporations and the eventual integration of the acquired assets. This development could impact the company's future growth trajectory and operational efficiency.